Astec Lifesciences Ltd

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 03 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has experienced a notable shift in price momentum, reflected in a 20.00% surge in its share price to ₹662.50 on 9 Sep 2026. Despite this sharp intraday gain, technical indicators present a nuanced picture, with a transition from bearish to mildly bearish trends and mixed signals across key momentum oscillators and moving averages.

At Rs 662.8, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Astec Lifesciences Ltd locked at its upper circuit of 20.0% on 8 Sep 2026, with buyers queuing and no sellers willing to part with shares.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest day gain of 1.06%, the stock’s broader technical profile and recent downgrade to a Strong Sell rating by MarketsMOJO highlight growing concerns among investors.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite a modest day gain of 1.11% to close at ₹566.30 on 2 Sep 2026, the stock continues to face significant headwinds as reflected in its technical indicators and relative performance against the broader market.

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has recently formed a Death Cross as its 50-day moving average (DMA) crossed below the 200 DMA. This technical development is widely regarded as a bearish signal, indicating a potential deterioration in the stock’s trend and raising concerns about its long-term price weakness.

Astec Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 03 August 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 15 August 2026, providing investors with the latest perspective on the company’s position.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has experienced a notable shift in its technical momentum, signalling a transition from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, reveal a complex picture that investors must carefully analyse amid the stock’s underperformance relative to the broader market.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s technical indicators reveal a sideways trend with mixed signals from MACD, RSI, and moving averages, underscoring the challenges faced by investors in navigating its price action.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has experienced a notable shift in its technical momentum, signalling a transition from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, reveal a complex picture that investors must carefully analyse amid the stock’s underperformance relative to the broader market.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 3 August 2026. This shift reflects deteriorating financial trends, subdued valuation appeal, weakening technical indicators, and declining overall quality metrics, signalling heightened risk for investors amid challenging market conditions.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bullish to sideways trends. The stock’s recent performance, coupled with deteriorating technical grades and a significant downgrade in its Mojo Grade to Strong Sell, highlights growing investor caution amid bearish pressures.

Astec Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astec Lifesciences Ltd, a micro-cap player in the Pesticides & Agrochemicals sector, has reported a flat financial performance for the quarter ended June 2026, signalling a notable shift from its previously positive growth trajectory. Despite a robust 20.5% growth in net sales over the nine-month period, the company’s quarterly revenue contracted by 8.3%, accompanied by deteriorating operational metrics and a downgrade in its Mojo Grade from Strong Sell to Sell.

Astec LifeSciences Ltd., a Mumbai-based manufacturer of agrochemicals and pharmaceutical intermediates, reported a consolidated net loss of ₹18.72 crores for Q1 FY27 ended June 2026, marking a 43.34% deterioration year-on-year compared to a loss of ₹33.04 crores in Q1 FY26. The company's revenue declined 8.26% YoY to ₹83.56 crores, reflecting persistent challenges in the agrochemical sector. The stock closed at ₹657.00 on July 31, 2026, down 27.45% over the past year, significantly underperforming both the Sensex and its sectoral peers.

Astec Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.